Wagar discusses LEAP trial findings with OncLive

Matthew Wagar, MD, fellow in the Division of Gynecologic Oncology, spoke with OncLive for a recent story about the phase 3 LEAP-001 trial and what it means for treating patients with advanced endometrial cancer.

In “Dr. Wagar on Lenvatinib Plus Pembrolizumab vs. Chemo in First-Line Advanced Endometrial Cancer,” Wagar explained how a mismatch repair-deficient (dMMR) population could favor lenvatinib plus pembrolizumab, meaning immunotherapy strategies for dMMR advanced endometrial cancer could delay chemotherapy for later.

“There wasn't really a difference in overall survival [OS] outcomes between the lenvatinib [plus] pembrolizumab up-front group vs the chemotherapy up-front group. [Data] didn't meet a specific prespecified criterion for progression-free survival [PFS] or OS. [Therefore,] chemotherapy remains the standard of care, particularly for [patients with pMMR] endometrial cancer. [However], in the dMMR group, there was quite a bit of a signal [favoring] the lenvatinib plus pembrolizumab arm."

Read the whole article here.

**by Ob-Gyn Communications Intern Paige Stevenson